FOXO4-DRI vs Spermidine
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
FOXO4-DRIAnti-Aging & LongevityCognitive Enhancement
Spermidine- Summary
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Spermidine is a naturally occurring polyamine found in all living cells, with exceptionally high concentrations in wheat germ, aged cheese, and human sperm. It is the most studied autophagy-inducing dietary compound, shown to extend lifespan across multiple species and reduce cardiovascular and cognitive aging.
- Half-Life
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- ~30–60 minutes, but gut bacteria produce it continuously; supplementation raises tissue levels over weeks
- Admin Route
- Subcutaneous, Intraperitoneal (research)
- Oral
- Research
- —
- —
- Typical Dose
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- 1–5 mg
- Frequency
- 3 consecutive days per cycle
- Once daily
- Key Benefits
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Induces autophagy — cellular self-cleaning
- Extends lifespan in yeast, flies, worms, and mice
- Reduces cardiovascular aging and arterial stiffness
- Reduces all-cause mortality (human epidemiological data)
- Neuroprotective: reduces amyloid and tau pathology
- Promotes hair growth (anagen phase activation)
- Reduces age-related immune decline
- Improves memory in aging models
- Side Effects
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Generally very well tolerated
- Rare: mild GI discomfort at high doses
- May temporarily reduce some gut bacteria species
- Rare: headache at initiation
- Stacks With
- —
- —